Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
 15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Miconazole at dosages up to 30 mg/kg/day was given intravenously to seven patients with complicated courses of disseminated coccidioidomycosis. Six had received treatment with amphotericin B previously and five of these patients could be evaluated for the efficacy of the treatment. In three patients the condition failed to respond to therapy, another patient required intratracheal administration of amphotericin B later, and the fifth patient had an equivocal response to treatment. Severe phlebitis, pruritus, nausea, vomiting, hyperlipidemia, and thrombocytosis were frequent side effects. These limited unfavorable results indicate that until controlled studies demonstrate its safety and efficacy, therapy with miconazole should be reserved for highly selected patients with disseminated coccidioidomycosis who cannot receive amphotericin B.
 ...
PMID:Miconazole for treatment of disseminated coccidioidomycosis. Unfavorable experience. 65 56

Intravenous miconazole can produce responses in patients with various manifestations of coccidioidal disease, even if they have failed to respond to amphotericin B. In 4 large series of 33, 33, 46 and 31 courses of miconazole for skin and soft tissue, chronic pulmonary, meningeal and skeletal coccidioidomycosis, response rates of 40, 72, 31 and 32%, respectively, were achieved; 60, 75, 78 and 56%, respectively, of those responding subsequently relapsed at the site(s) of earlier involvement. This suggests that the therapeutic effect of the relatively brief courses used (mean, 1 to 3 months) is fungistatic in vivo. Common side effects of intravenous miconazole include phlebitis, pruritus, anaemia, thrombocytosis, hyponatraemia, nausea, hyperlipidaemia, vomiting, central nervous system effects, and rashes. The place of miconazole relative to amphotericin B and ketoconazole has not been determined, and requires further comparative studies. Information on the results of different regimens, particularly longer courses, would also be of interest.
 ...
PMID:Miconazole in the treatment of coccidioidomycosis. 635 86

The incidence of thromboses among young women has increased with widespread use of oral contraceptives (OCs) due to the significant thromboembolic risk of estrogen. Estrogens intervene at the vascular, platelet, and plasma levels as a function of hormonal variations in the menstrual cycle, increasing the aggregability of the platelets and thrombocytes, accelerating the formation of clots, and decreasing the amount of antithrombin III. Estrogens are used in medicine to treat breast and prostate cancers and in gynecology to treat dysmenorrhea, during the menopause, and in contraception. Smoking, cardiovascular disease and hypertension, hypercholesterolemia, and diabetes are contraindicators to estrogen use. Thrombosis refers to blockage of a blood vessel by a clot or thrombus. Before estrogens are prescribed, a history of phlebitis, obesity, hyperlipidemia, or significant varicosities should be ruled out. A history of venous thrombosis, hyperlipoproteinemia, breast nodules, serious liver condition, allergies to progesterone, and some ocular diseases of vascular origin definitively rule out treatment with estrogens. A family history of infarct, embolism, diabetes, cancer, or vascular accidents at a young age signals a need for greater patient surveillance. All patients receiving estrogens should be carefully observed for signs of hypertension, hypercholesterolemia, hypercoagulability, or diabetes. Nurses have a role to play in carefully eliciting the patient's history of smoking, personal and family medical problems, and previous and current laboratory results, as well as in informing the patients of the risks and possible side effects of OCs, especially for those who smoke. Nurses should educate patients receiving estrogens, especially those with histories of circulatory problems, to avoid standing in 1 position for prolonged periods, avoid heat which is a vasodilator, avoid obesity, excercise regularly, wear appropriate footgear, and follow other good health practices.
 ...
PMID:[Estrogens and vascular thrombosis]. 692 85

Deep vein thrombophlebitis (DVT) and pulmonary emboli (PE) have been uncommonly reported manifestations of systemic lupus erythematosus (SLE). This may be partly due to their being masked by other more familiar lesions of the lungs and extremities in SLE. We have identified 17 patients with SLE from a population of 180 being followed up prospectively who had 21 attacks of DVT and/or PE. Of the total of 21 episodes the SLE was considered to be active in 14, inactive in 6, and variable in a patient with recurring phlebitis. The incidence of hyperlipidaemia, smoking history, and use of birth control medication or corticosteroids was not higher in these patients. These clinical findings thus constitute additional features of SLE occurring in about 9% of patients and may be significance for morbidity and mortality.
 ...
PMID:Venous syndromes and pulmonary embolism in systemic lupus erythematosus. 743 59

Epidemiological studies clearly indicate that combined oral contraceptives (OCs) increase risks of vascular thromboses. The risk of myocardial infarct is increased by 3 for combined OC users aged 30-39 and by 5 for those aged 40-44. Risks of deep phlebitis and cerebral thromboses are also 5 times greater in OC users. The effects of OCs on serum lipid levels depend on the dose and type of estrogens and progestin. Ethinyl estradiol causes an increase in triglycerides and HDL cholesterol, while progestins tend to increase total cholesterol and decrease HDL cholesterol. Low-dose combined OCs have slight or no effect on cholesterol, HDL cholesterol or triglycerides. Moderately dosed combined OCs elevate triglycerides but their effects on total cholesterol and HDL are moderate. High dose combined OCs increase triglyceride and cholesterol levels. The combined effects of the estrogen and progestin in high dose pills usually increase HDL cholesterol, but there is some doubt as to whether the increase is beneficial. Although all combined OCs have deleterious effects on serum lipids, only persons predisposed to hyperlipidemia are truly at risk. Young women using OCs require systematic control, of serum lipid and lipoprotein levels. Low-dose formulations are generally preferable. Standard or high dosed OCs can cause disturbances of glucose metabolism in predisposed women, but risks of patent diabetes are small. Glucose intolerance developed during pill use is not always reversible. The risk appears more serious with pills containing estranes or norgestrel than with those containing pregnanes. Low-dose pills entail less deterioration than higher dosed pills. Low-dose progestin-only pills also have deleterious effects. OCs interfere with glucose metabolism in part by creating an effect of peripheral insulin resistance and in part by diminishing the insulin-secreting capacities of the islets of Langerhans. All OCs are contraindicated in women with histories of gestational diabetes or glucose intolerance. Insulin-dependent diabetes in adolescents is a relative contraindication. Regular surveillance is required of weight and blood sugar for normal women using OCs. Estrogens have been the major factor identified in variations of coagulation factors and fibrinolysis in OC users. Platelet aggregation has been less well studied. OCs should be avoided in case of hypercoagulative states of platelet hyperaggregation.
 ...
PMID:[Metabolic risks of oral contraception]. 1228 76